ReviewInternational journal of molecular sciences2022
Evasion of Antimicrobial Activity in
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Synergetic attenuated inflammatory response and increased apoptosis confer high pathogenicity ofVirulence · 2026Article
- Genomic landscape of 340 virulent Acinetobacter bacteriophages reveals anti-CRISPR-enriched candidates for therapeutic prioritization.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Therapeutic milestones against multidrug resistant Acinetobacter baumannii: from legacy antibiotics to Zosurabalpin.Archives of microbiology · 2026Review
- Bacterial mutation dynamics emerging insights into virulence evolution and drug resistance. A review study.Frontiers in medicine · 2026Review
- Identification, resistance mechanisms, and innovative therapeutic approaches againstFrontiers in microbiology · 2026Review
- Comparison between cefepime and carbapenem therapy for deep-seated AmpC-producingAntimicrobial agents and chemotherapy · 2025Article
- Pseudomonas spp. and antimicrobial resistance: unlocking new horizons with 1-hydroxyphenazine.Folia microbiologica · 2025Review
- Design of Novel Saposin-like Bacteriocins Using a Hybrid Approach.Probiotics and antimicrobial proteins · 2025Article
- Carbapenem-ResistantMicroorganisms · 2025Review
- HypervirulentAntibiotics (Basel, Switzerland) · 2025Review
- Unseen Enemy: Mechanisms of Multidrug Antimicrobial Resistance in Gram-Negative ESKAPE Pathogens.Antibiotics (Basel, Switzerland) · 2025Review
- Advancements in AI-driven drug sensitivity testing research.Frontiers in cellular and infection microbiology · 2025Review
- The intricacies ofFrontiers in microbiology · 2025Review
- Article
- An Overview of the Recent Advances in Antimicrobial Resistance.Microorganisms · 2024Review
- Insights into Kinases of ESKAPE Pathogens for Therapeutic Interventions.Cardiovascular & hematological agents in medicinal chemistry · 2024Review
- Evaluation of Antibiotic Resistance Mechanisms in Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Review
- Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii.PLoS pathogens · 2023Article
- Changes in Antibiotic Resistance ofJournal of clinical medicine · 2023Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.